CAS 54143-55-4|flecainide
| Common Name | flecainide | ||
|---|---|---|---|
| CAS Number | 54143-55-4 | Molecular Weight | 414.34300 |
| Density | 1.286 g/cm3 | Boiling Point | 434.9ºC at 760 mmHg |
| Molecular Formula | C17H20F6N2O3 | Melting Point | 105-1070C |
| MSDS | / | Flash Point | 216.8ºC |
| Symbol | GHS02, GHS06, GHS08 | Signal Word | Danger |
Names
| Name | flecainide |
|---|---|
| Synonym | More Synonyms |
flecainide BiologicalActivity
| Description | Flecainide is a potent and orally active antiarrhythmic agent. Flecainide blocks the cardiac fast inward Na+ current (INa) and the rapid component of the delayed rectifier K+ current. Flecainide prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide has the potential for the research of fetal tachycardias[1][2][3]. |
|---|---|
| Related Catalog | Signaling Pathways >>Membrane Transporter/Ion Channel >>Sodium ChannelResearch Areas >>Cardiovascular DiseaseSignaling Pathways >>Membrane Transporter/Ion Channel >>Potassium Channel |
| References | [1]. Echt DS, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991 Mar 21;324(12):781-8. [2]. Aliot E, et al. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace. 2011 Feb;13(2):161-73. [3]. Allan LD, et al. Flecainide in the treatment of fetal tachycardias. Br Heart J. 1991 Jan;65(1):46-8. |
Chemical & Physical Properties
| Density | 1.286 g/cm3 |
|---|---|
| Boiling Point | 434.9ºC at 760 mmHg |
| Melting Point | 105-1070C |
| Molecular Formula | C17H20F6N2O3 |
| Molecular Weight | 414.34300 |
| Flash Point | 216.8ºC |
| Exact Mass | 414.13800 |
| PSA | 59.59000 |
| LogP | 4.16040 |
| InChIKey | DJBNUMBKLMJRSA-UHFFFAOYSA-N |
| SMILES | O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F |
| Storage condition | Refrigerator |
Safety Information
| Symbol | GHS02, GHS06, GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H225-H301 + H311 + H331-H370 |
| Precautionary Statements | P210-P260-P280-P301 + P310-P311 |
| Hazard Codes | F,T |
| Risk Phrases | 11-23/24/25-39/23/24/25 |
| Safety Phrases | 7-16-36/37-45 |
| RIDADR | 3249 |
| Packaging Group | III |
| Hazard Class | 6.1(b) |
Articles32
More Articles| Multiple modes of ryanodine receptor 2 inhibition by flecainide. Mol. Pharmacol. 86(6) , 696-706, (2014) Catecholaminergic polymorphic ventricular tachycardia (CPVT) causes sudden cardiac death due to mutations in cardiac ryanodine receptors (RyR2), calsequestrin, or calmodulin. Flecainide, a class I ant... | |
| A misguided 'pill in the pocket' approach with flecainide leading to cardiac arrest. BMJ Case Rep. 2012 , doi:10.1136/bcr-2012-006868, (2012) | |
| A case of near-fatal flecainide overdose in a neonate successfully treated with sodium bicarbonate. J. Emerg. Med. 44(4) , 781-3, (2013) Flecainide is a class IC antidysrhythmic primarily indicated for ventricular dysrhythmias and supraventricular tachycardia (SVT). Class IC antidysrhythmic overdose has a reported mortality of 22%, and... |
Synonyms
| N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide |
| FLECAINTDE BASE |
| N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide |
| 2,5-bis-(2,2,2-Trifluoroethoxy)-n-(2-piperidyl-methyl)-benzamid |
| EINECS 200-659-6 |
| N-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide |
| Flecainide |
| Benzamide,N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy) |
| Flecanide |
| Flecaine |
| MFCD00864713 |
